Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Notes Payables: 2023-2024

  • Zhengye Biotechnology Holding's Notes Payables fell 8.05% to $10.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.2 million, marking a year-over-year decrease of 8.05%. This contributed to the annual value of $10.2 million for FY2024, which is 9.75% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Notes Payables stood at $10.2 million for Q4 2024, which was down 8.05% from $11.1 million recorded in Q4 2023.
  • Zhengye Biotechnology Holding's Notes Payables' 5-year high stood at $11.1 million during Q4 2023, with a 5-year trough of $10.2 million in Q4 2024.
  • Its 2-year average for Notes Payables is $10.6 million, with a median of $10.6 million in 2023.
  • Data for Zhengye Biotechnology Holding's Notes Payables shows a maximum YoY declined of 8.05% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Notes Payables (Quarterly) stood at $11.1 million in 2023, then dropped by 8.05% to $10.2 million in 2024.